Atovaquone Oral Suspension Recalled for Bacillus cereus Contamination
Camber Pharmaceuticals is recalling Atovaquone Oral Suspension due to contamination by Bacillus cereus bacteria. The contamination was discovered during testing of repackaged medication.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This FDA Class I recall requires a minimum severity of 4 per regulatory guidelines. The actual detection of Bacillus cereus contamination in a prescription medication justifies the Severe classification despite no reported illnesses.
Plain-English summary
Camber Pharmaceuticals Inc. is recalling Atovaquone Oral Suspension USP (750 mg/5 mL) because testing identified Bacillus cereus contamination in repackaged product. The contaminated lot (E220182, expiring December 31, 2023) includes 1,568 bottles. This is an FDA Class I recall, the agency's most serious classification.
The recalled medication was distributed nationwide in the United States. Patients taking this medication should contact their healthcare provider immediately. Do not continue use of the affected product without consulting a healthcare provider about alternatives.
The recalled product
- Product
- ATOVAQUONE (ATOVAQUONE)
- Brand
- ATOVAQUONE
- Manufacturer
- Camber Pharmaceuticals Inc.
- Category
- Drug — Antimalarial
- Affected units
- 1,568
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# E220182
- Exp. 12/31/2023
UPCs (1)
- 0331722629218
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ATOVAQUONE
- SevereAtovaquone Oral Suspension Recalled for Cohnella Bacteria Contamination
FDA (Drugs) · 2024-10-23
Same manufacturer · Camber Pharmaceuticals Inc.
See all →- ModerateLacosamide oral solution recalled for failed excipient specifications
FDA (Drugs) · 2022-12-21
- SevereCamber Pharmaceuticals Recalls Losartan Potassium Tablets Due to NMBA Contamination
FDA (Drugs) · 2019-03-27
- SevereCamber Pharmaceuticals Recalls Losartan Potassium Tablets Due to NMBA Contamination
FDA (Drugs) · 2019-03-27
- SevereCamber Pharmaceuticals Recalls Losartan Potassium Tablets Due to NMBA Contamination
FDA (Drugs) · 2019-03-27
Same hazard · microbial contamination
See all →- HighMedline IV Start Kits Recalled for Potential Sterility Breach
FDA (Devices) · 2026-09-09
- HighMedline Convenience Kits Recalled for Potential Sterility Breach
FDA (Devices) · 2026-09-09
- SevereMedline Convenience Kits Recalled for Potential Sterility Breach
FDA (Devices) · 2026-09-09
- SevereMedline Blood Culture Kits Recalled for Potential Sterility Breach
FDA (Devices) · 2026-09-09
- SevereMedline Eye and Cataract Kits Recalled for Potential Sterility Breach
FDA (Devices) · 2026-09-09